Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chiron’s Adjuvant Could Quadruple Flu Vaccine Capacity, CEO Pien Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm will meet with FDA to determine the regulatory pathway for the MF59 adjuvant in 2006.

You may also be interested in...

Chiron Minority Shareholder Will Oppose Novartis Takeover

Shareholder ValueAct Capital owns 5% of Chiron's shares and 9% of non-Novartis-owned shares.

Chiron Expects Full Fluvirin Vaccine Production In 2006-2007

Fluvirin flu vaccine production capacity for 2005-2006 will be lower than the previous estimate of 18 mil.-25 mil. doses due to a shortened production season, CEO Pien says.

FDA Releases Three Lots Of Chiron's Fluvirin

Chiron received approval for its flu vaccine Sept. 14 after adequately addressing FDA's manufacturing concerns.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts